Leo Pharma has gained marketing authorisation from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its topical pan-Janus kinase (JAK) inhibitor, Anzupgo (delgocitinib) 20mg/g cream, to treat chronic hand eczema (CHE) in Britain.
The approval enables the treatment of adults with moderate to severe CHE when topical corticosteroids are inadequate or inappropriate.
The decision was based on the positive outcomes of the Phase III programme, which encompassed the DELTA 1 and DELTA 2 trials. The trials assessed the cream’s efficacy and safety against a cream vehicle, meeting their primary and secondary goals.
Subjects from the DELTA 1 and DELTA 2 trials were given the opportunity to join the DELTA 3 trial, a 36-week open-label extension study.
LEO Pharma UK and Ireland vice-president and general manager Leanne Walsh stated: “Today’s MHRA approval of delgocitinib cream marks a significant milestone for adults in Great Britain living with moderate to severe chronic hand eczema.
“This approval offers a new treatment paradigm and demonstrates our commitment to addressing the unmet needs of people living with skin conditions.”
The cream targets the JAK-STAT signalling pathway involved in CHE pathogenesis. The condition is marked by skin barrier dysfunction, inflammation and changes in the skin microbiome.
The current approval of delgocitinib cream adds to its existing authorisations in the European Union and Switzerland for the same indication.
LEO Pharma obtained exclusive development and commercialisation rights to the cream for dermatological uses globally, excluding Japan, through a license agreement with Japan Tobacco (JT) in 2014. JT holds the rights in Japan.
In September 2024, the European Commission (EC) granted marketing authorisation for delgocitinib cream to treat adults with moderate to severe CHE.
LEO Pharma UK and Ireland is working with the National Institute for Health and Care Excellence (Nice) to ensure the cream’s availability on the National Health Service (NHS).
Chronic hand eczema is a complex and variable inflammatory skin condition, with primary symptoms such as itching and pain affecting the hands and wrists.
Source: pharmaceutical-technology.com
GSK has gained US Food and Drug Administration (FDA) breakthrough therapy designation (BTD) for its B7-H3-targeted antibody-drug conjugate (ADC), GSK’227, to treat adults with relapsed or refractory osteosarcoma who have progressed on a minimum of two previous lines of therapy.
As part of its long-term plans in the country, US drugmaker Merck & Co., operating as MSD outside of North America, has acquired WuXi Biologics’ site in Dundalk, Ireland, for about $500 million. The deal was announced through Ireland’s Foreign Direct Investment Agency (IDA) and MSD’s Ireland unit.
Galapagos, a biotechnology company headquartered in Belgium, plans to split into two entities: a newly formed company (name to be announced at a later date) that will focus on building a pipeline of innovative drugs through transformative transactions, and Galapagos, which will continue to develop its cell therapy manufacturing platform in oncology.
